Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Pharmaron Beijing Co., Ltd. Class H ( (HK:3759) ) just unveiled an update.
Pharmaron Beijing has proposed a new eight-member fourth-session board structure, reducing the number of directors from nine to eight to improve decision-making efficiency and corporate governance. The slate includes three executive directors, one non-executive director, three independent non-executive directors, and an employee representative director, with two current directors not seeking re-election after their terms expire.
The nomination committee and board state that all proposed directors meet Chinese company law, ChiNext, and Hong Kong listing requirements, including independence thresholds and limits on management representation. The new board term will run for three years starting from the conclusion of the 2025 annual general meeting, subject to shareholder approval and a separate employee representative election, signalling a governance refresh aligned with regulatory standards and the company’s business development needs.
The most recent analyst rating on (HK:3759) stock is a Buy with a HK$28.10 price target. To see the full list of analyst forecasts on Pharmaron Beijing Co., Ltd. Class H stock, see the HK:3759 Stock Forecast page.
More about Pharmaron Beijing Co., Ltd. Class H
Pharmaron Beijing Co., Ltd. is a pharmaceutical research and development services provider based in the People’s Republic of China, listed in Hong Kong. The group focuses on supporting global drug discovery and development through contract research and related services for biopharmaceutical companies and other healthcare stakeholders.
Average Trading Volume: 5,571,416
Technical Sentiment Signal: Buy
Current Market Cap: HK$55.97B
See more data about 3759 stock on TipRanks’ Stock Analysis page.